Rare Disease Bio Company Executives Cash Out Millions in Shares

Executives at rare-disease–focused biotech Centessa Pharmaceuticals plc (NASDAQ: CNTA) have sold shares under pre-established Rule 10b5-1 trading plans. On March 13, Chief Business Officer Gregory M. Winehop sold about 70,000 common shares on the open market, generating roughly $1.93 million and reducing his direct holdings to around 65,000 shares. On March 16 and 17, Chief Human Resources Officer Karen M. Anderson exercised stock options to acquire approximately 70,000 shares and immediately sold them, raising about $2.1 million and leaving her with roughly 60,000 shares.

Earlier this month, Centessa disclosed via its Japanese partner Nxera Pharma that achievement of an early development milestone triggered a payment obligation of about $3 million. At a February investor event, newly appointed CEO Mario Alberto Arcadi highlighted the potential to initiate a registrational clinical trial this year for ORX750—an orexin-2 receptor agonist candidate for narcolepsy and other rare sleep disorders—emphasizing 2026 as a “pivot year” for the company.

Headquartered in Altrincham, UK, Centessa Pharmaceuticals is a clinical-stage biopharmaceutical company that raised over $370 million in its 2021 Nasdaq IPO to develop therapies for rare and neurological/neurodegenerative diseases. The company has since streamlined its previously diversified pipeline to focus on its orexin platform, led by ORX750, concentrating on narcolepsy and idiopathic hypersomnia.